glp-1 employer healthcare costs The Health and Spending Effects of GLP-1s Employers Grapple with Claims Costs

"Lisdexamfetamine - Shionogi/Takeda"

Its shares fell nearly 50 percent in 2025 and are down a further 15 percent this year, while the company now expects sales and profit to decline 5 percent13 percent in 2026, mainly because of US pricing pressure and loss of semaglutide exclusivity in markets such as Canada and China, according to CNBC

Per Kaisers 2025 Comprehensive Formulary, Ozempic is typically in tier 3, so youll likely still have some out-of-pocket costs

Although underlying mechanisms are still not completely explained, the interaction with RAAS seems to play a relevant role

In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy